Trump wins U.S. election | Expert analysis on e-cigarette policy direction under the next administration

Nov.06.2024
Trump wins U.S. election | Expert analysis on e-cigarette policy direction under the next administration
Tom Beaudet, CEO of U.S. compliance firm Accorto, reviewed the effectiveness of past bipartisan policies and predicts that the FDA will improve its review process, allowing e-cigarette products to gain market approval more quickly in the future.

The results of the 2024 U.S. presidential election have been revealed, with Donald Trump elected as the new president. As the largest e-cigarette market in the world, the direction and regulatory policies of the U.S. market have significant global implications. How the new administration will regulate e-cigarettes and the future of the U.S. e-cigarette market are questions drawing global industry attention. As a leading global vaping technology media and think tank, 2Firsts quickly connected with U.S. compliance experts to provide the most authoritative analysis.

 

Tom Beaudet, CEO of U.S. compliance firm Accorto, shared with 2Firsts his thoughts on the regulatory approaches and actions of both the Trump administration and the current Democratic government on e-cigarettes. He emphasized that, during the current administration's four years, only 9 harm-reduction product applications were approved, despite millions of applications being submitted. He predicts that under the next administration, the FDA may gradually establish a clearer market entry pathway, helping companies that submit complete scientific data gain market access more quickly.

 

Trump wins U.S. election | Expert analysis on e-cigarette policy direction under the next administration
Accorto CEO Tom Beaudet | Image source: 2Firsts

 

Read the full perspective from Tom Beaudet:

 

  • Several weeks ago, ex President Donald Trump made the statement that he saved flavored vapes in 2020 and that, if he is elected again, he will save flavors again. However, it must be remembered that flavored closed pod systems were banned during the Trump presidency.

 

  • During the past 4 years, FDA has only approved 9 new harm reduction products, although applications have been submitted for millions of new products.  Although the vast majority of those applications were not complete with the scientific data needed for substantive review by the CTP Office of Science, several companies did submit high quality applications and are still awaiting a final decision.  Many question why we should expect anything different under another Democratic Party administration.

 

  • There is hope, regardless of who walks away victorious on November 5.  The US VTA, led by their president Tony Abud, has been aggressively working to educate members of Congress from both parties about the life saving potential of Nicotine Harm Reduction products and the importance of making changes at FDA to repair the currently broken review process.  Regardless of who wins tomorrow, we should expect to see improvements in the PMTA review process where applications who spend the money and time to submit high quality applications have a known and proven pathway to a Market Granted Order.  As more products are approved and we develop a pool of predicate products to reference, the known pathway to success will be come more and more established.

 


 

2Firsts will continue to bring the latest reports and interpretations on U.S. e-cigarette policies.

 

Disclaimer: This article represents only the views of the expert.

Special Report | Anti-Vaping Campaign in the Baltics Goes Sideways
Special Report | Anti-Vaping Campaign in the Baltics Goes Sideways
2Firsts analyzes vaping regulations across the Baltic states. Following Latvia’s flavor ban, tax revenues fell and the black market expanded, while similar measures in Estonia and Lithuania have also failed to deliver results. The region’s anti-vaping policies are now triggering market imbalance and policy reassessment.
Oct.13
British Museum Ends Long-Running Sponsorship with Japan Tobacco International
British Museum Ends Long-Running Sponsorship with Japan Tobacco International
According to The Guardian, the British Museum has ended its 15-year sponsorship with Japan Tobacco International after government inquiries into whether the deal breached WHO tobacco-control rules. Critics had long opposed the partnership, while the museum said sponsorship remains essential for its financial stability and public access.
Nov.20
SKE Partners with 7-Eleven Korea, Placing Its Products in Over 5,700 Stores
SKE Partners with 7-Eleven Korea, Placing Its Products in Over 5,700 Stores
According to an SKE release published on PR Newswire, the company is expanding its presence in the Korean market through convenience store and specialty retail channels. SKE has partnered with 7-Eleven Korea, placing its products in more than 5,700 stores nationwide, and is also working with OG9’s offline retail and B2B distribution network. On the product side, SKE is focusing on promoting the Crystal Bar TB1000 and Cloud Zero in Korea.
Nov.19 by 2FIRSTS.ai
Organigram Global Appoints Former BAT Global Head of Strategy James Yamanaka as Chief Executive Officer
Organigram Global Appoints Former BAT Global Head of Strategy James Yamanaka as Chief Executive Officer
Organigram Global has named James Yamanaka, previously Global Head of Strategy at British American Tobacco (BTI), as its new CEO. His appointment is expected to take effect around January 15, 2026, and he will also join the company’s board. Yamanaka brings more than 20 years of strategic and managerial experience from roles across Europe and Asia at BTI.
Nov.26
Indonesian Police to Crack Down on Etomidate-Laced Vapes
Indonesian Police to Crack Down on Etomidate-Laced Vapes
Indonesia’s National Police Criminal Investigation Department (Bareskrim Polri) will continue to take enforcement action against users and distributors of etomidate-laced vape liquids, even though the substance is not yet classified as a narcotic. Brigadier General Eko Hadi Santoso, Director of Narcotics Crimes, said etomidate is an anaesthetic drug regulated under Health Law No. 17 of 2023, but has not been listed as a narcotic or psychotropic substance.
Oct.23 by 2FIRSTS.ai
Bangladesh Tobacco Control Group Urges Reversal of Philip Morris Nicotine Pouch Factory Approval
Bangladesh Tobacco Control Group Urges Reversal of Philip Morris Nicotine Pouch Factory Approval
Advocates say the economic authority’s decision contradicts national health goals and violates a Supreme Court directive banning new tobacco ventures.
Oct.27 by 2FIRSTS.ai